BIOLUX P-III is a prospective, international, multi-centre, postmarket all-comers registry to collect clinical performance data on the Passeo-18 Lux paclitaxel releasing balloon catheter in the treatment of atherosclerotic disease of the infrainguinal arteries.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Freedom from Major Adverse Events (MAE)
Timeframe: 6 months
Freedom from clinically-driven Target Lesion Revascularization (TLR)
Timeframe: 12 months